首页|复方利多卡因乳膏在中国健康受试者体内的生物等效性研究

复方利多卡因乳膏在中国健康受试者体内的生物等效性研究

扫码查看
目的 研究受试制剂复方利多卡因乳膏和参比制剂利丙双卡因乳膏在中国健康受试者中的药代动力学特征并评价两种制剂的生物等效性.方法 用单中心、单剂量、随机、开放、两周期、双序列和双交叉设计.纳入40例健康受试者,每周期将受试制剂或参比制剂60 g在空腹状态下分别涂抹于双侧大腿前面皮肤(每侧200 cm2,共400 cm2),并在给药操作完成后保持药物停留至少5 h.用液相色谱-串联质谱(LC-MS/MS)方法测定血浆中利多卡因和丙胺卡因的浓度,用WinNonlin 8.0软件计算药代动力学参数,评价两种制剂的生物等效性.结果 受试者双侧大腿涂抹受试制剂复方利多卡因乳膏与参比制剂利丙双卡因乳膏后,血浆中利多卡因药代动力学参数:Cmax分别为(167.27±91.33)和(156.13±66.86)ng·mL-1,AUC0-t分别为(1 651.78±685.09)和(1 636.69±617.23)ng·mL-1·h,AUC0-∞ 分别为(1 669.85±684.65)和(1 654.37±618.30)ng·mL-1·h,调整后几何均值比值分别为104.49%、101.88%和 101.89%,其 90%置信区间分别为 98.18%~111.20%、97.80%~106.13%和 97.87%~106.07%,均落在 80.00%~125.00%.血浆中丙胺卡因药代动力学参数:Cmax分别为(95.66±48.84)和(87.52±39.16)ng·mL-1,AUC0-t分别为(790.86±263.99)和(774.14±256.42)ng·mL-1·h,AUC0-∞ 分别为(807.27±264.67)和(792.84±254.06)ng·mL-1·h,调整后几何均值比值分别为107.34%、103.55%和102.98%,其90%置信区间分别为101.69%~113.31%、99.94%~107.30%和 99.65%~106.43%,均落在 80.00%~125.00%.结论 受试制剂复方利多卡因乳膏和参比制剂利丙双卡因乳膏具有生物等效性.
Bioequivalence study of compound lidocaine cream in healthy Chinese subjects
Objective To study the pharmacokinetic characteristics of the test formulation of compound lidocaine cream and reference formulation of lidocaine and prilocaine cream in Chinese healthy subjects and to evaluate whether there is bioequivalence between the two formulations.Methods A single-center,single-dose,randomized,open-label,two-period,two-sequence,crossover design was used.This study included 40 healthy subjects,and in each period,test formulation or reference formulation 60 g was applied to the skin in front of both thighs(200 cm2 each side,a total of 400 cm2)under fasting conditions,and the drug was left on for at least 5 h after application.The concentrations of lidocaine and prilocaine in plasma were determined using liquid chromatography-tandem mass spectrometry(LC-MS/MS)method.Pharmacokinetic parameters were calculated using WinNonlin 8.0 software to evaluate the bioequivalence of the two formulations.Results After the application of the test formulation compound lidocaine cream and the reference formulation lidocaine and prilocaine cream on both thighs of the subjects,the pharmacokinetic parameters of lidocaine in plasma were as follows:Cmax were(167.27±91.33)and(156.13±66.86)ng·mL-1,AUC0-t were(1 651.78±685.09)and(1 636.69±617.23)ng·mL-1·h,AUC0-∞ were(1 669.85±684.65)and(1 654.37±618.30)ng·mL-1·h,the adjusted geometric mean ratios were 104.49%,101.88%and 101.89%,respectively,with 90%confidence intervals of 98.18%-111.20%,97.80%-106.13%and 97.87%-106.07%,all within the range of 80.00%-125.00%.The pharmacokinetic parameters of prilocaine in plasma were as follows:Cmax were(95.66±48.84)and(87.52±39.16)ng·mL-1,AUC0-t were(790.86±263.99)and(774.14±256.42)ng·mL-1·h,AUC0_m were(807.27±264.67)and(792.84±254.06)ng·mL-1 h,the adjusted geometric mean ratios were 107.34%,103.55%and 102.98%,respectively with 90%confidence intervals of 101.69%-113.31%,99.94%-107.30%and 99.65%-106.43%,all within the range of 80.00%-125.00%.Conclusion The test formulation compound lidocaine cream and the reference formulation lidocaine and prilocaine cream are bioequivalent.

compound lidocaine creamhealthy subjectbioequivalencepharmacokineticsliquid chromatography-tandem mass spectrometry(LC-MS/MS)

常梦琦、孙宇琦、徐秋瑾、钱希曦、赵迎春、曹艳、王柳、张程、于栋梁

展开 >

徐州市中心医院Ⅰ期临床研究中心,江苏徐州 221111

徐州市中心医院药物临床试验机构办公室,江苏徐州 221111

徐州立兴佳正医药科技有限公司,江苏徐州 221008

诺为泰医药科技(上海)有限公司,上海 200020

展开 >

复方利多卡因乳膏 健康受试者 生物等效性 药代动力学 液相色谱-串联质谱

江苏省新药研究与临床药学重点实验室开放研究项目

KFKT-2110

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(9)
  • 11